Pharmaco-economic study of intensive chemotherapy with peripheral blood progenitor cell support for advanced breast cancer

Oncology Reports

Volumn 8, Issue 5, 2001, Pages 1013-1017

  Pinguet, Frédéric ^a  

^a CENTRE VAL D AURELLE   (France)

Author keywords

Breast cancer; Intensive chemotherapy; Peripheral blood progenitor cell; Pharmaco economic study

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; MELPHALAN; MITOXANTRONE;

ADULT; ARTICLE; BREAST TUMOR; CANCER STAGING; COST; DISEASE MANAGEMENT; ECONOMICS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; MIDDLE AGED; PHARMACOECONOMICS; REMISSION; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COSTS AND COST ANALYSIS; CYCLOPHOSPHAMIDE; DISEASE MANAGEMENT; ECONOMICS, PHARMACEUTICAL; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MIDDLE AGED; MITOXANTRONE; NEOPLASM STAGING; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING;

EID: 0035461317     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.8.5.1013     Document Type: Article

References (1)

1. Hillner BE, Smith TJ and Desch CE: Efficacy and costeffectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055-2061, 1992.